pubmed.ncbi.nlm.nih.gov

Biochemical Mechanisms Underlying Psychedelic-Induced Neuroplasticity - PubMed

  • ️Sat Jan 01 2022

Review

Biochemical Mechanisms Underlying Psychedelic-Induced Neuroplasticity

David E Olson. Biochemistry. 2022.

Abstract

In addition to producing profound subjective effects following acute administration, psychedelic compounds can induce beneficial behavioral changes relevant to the treatment of neuropsychiatric disorders that last long after the compounds have been cleared from the body. One hypothesis with the potential to explain the remarkable enduring effects of psychedelics is related to their abilities to promote structural and functional neuroplasticity in the prefrontal cortex (PFC). A hallmark of many stress-related neuropsychiatric diseases, including depression, post-traumatic stress disorder (PTSD), and addiction, is the atrophy of neurons in the PFC. Psychedelics appear to be particularly effective catalysts for the growth of these key neurons, ultimately leading to restoration of synaptic connectivity in this critical brain region. Furthermore, evidence suggests that the hallucinogenic effects of psychedelics are not directly linked to their ability to promote structural and functional neuroplasticity. If we are to develop improved alternatives to psychedelics for treating neuropsychiatric diseases, we must fully characterize the molecular mechanisms that give rise to psychedelic-induced neuroplasticity. Here, I review our current understanding of the biochemical signaling pathways activated by psychedelics and related neuroplasticity-promoting molecules, with an emphasis on key unanswered questions.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.

Chemical structures of psychoplastogens from various pharmacological classes

Figure 2.
Figure 2.

Biochemical pathways activated by psychedelics. Pathways with with strong, moderate, and weak supporting evidence are indicated with black, dark grey, and light grey arrows, respectively.

Similar articles

Cited by

References

    1. Catlow BJ; Song S; Paredes DA; Kirstein CL; Sanchez-Ramos J Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning. Exp. Brain Res, 2013, 228, 481–491. - PubMed
    1. Hibicke M; Landry AN; Kramer HM; Talman ZK; Nichols CD Psychedelics, but Not Ketamine, Produce Persistent Antidepressant-like Effects in a Rodent Experimental System for the Study of Depression. ACS Chem. Neurosci 2020, 11, 864–871. - PubMed
    1. Cameron LP; Benson CJ; Dunlap LE; Olson DE Effects of N,N-dimethyltryptamine (DMT) on rat behaviors relevant to anxiety and depression. ACS Chem. Neurosci 2018, 9, 1582–1590. - PMC - PubMed
    1. Cameron LP; Benson CJ; DeFelice BC; Fiehn O; Olson DE Chronic, Intermittent Microdoses of the Psychedelic N,N-Dimethyltryptamine (DMT) Produce Positive Effects on Mood and Anxiety in Rodents. ACS Chem. Neurosci 2019, 10, 3261–3270. - PMC - PubMed
    1. Hesselgrave N; Troppoli TA; Wulff AB; Cole AB; Thompson SM Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice. Proc Natl Acad Sci U S A. 2021, 118, e2022489118. - PMC - PubMed

Publication types

MeSH terms

Substances